Amgen Inc.

James Richard Falsey

Robert Michael Rzasa

Elizabeth M Doherty

Ning Chen

Andrew Stewart Tasker

Liping H Pettus

Celia Dominguez

Mark Henry Norman

Dawei Zhang

Hui-Ling Wang

Leslie Phillip Miranda

Andreas Reichelt

Jennifer Rebecca Allen

Holger Monenschein

Thomas T Nguyen

Bin Wu

Matthew R Kaller

Michael J Frohn

Christopher Harold Fotsch

Alexander J Pickrell

Paul E Harrington

Markian Myroslaw Stec

Thomas Nixey

Shannon Rumfelt

Vassil I Ognyanov

Jiawang Zhu

Kaustav Biswas

Erin F DiMauro

Kelvin C Sham

Bradley J Herberich

Jerry Ryan Holder

Guomin Yao

Partha P Chakrabarti

Jodie Katon

Fang-Tsao Hong

Roxanne Kay Kunz

Essa Hu Harrington

Christopher Hulme

Christopher Michael Tegley

Yuan Cheng

Frank Chavez

Kelvin K C Sham

Seifu Tadesse

Junming Yie

Justin K Murray

Frenel Fils De Morin

Shu-Chen Lu

Malgorzata Wanska

Chawita Netirojjanakul

Shanaka Stanislaus

Matthew W Martin

Craig E Masse

Gang Liu

Joseph L Kim

Jean-Christophe P Harmange

Brian K Albrecht

Jean E Bemis

Vinod Francis Patel

Brian Lewis Hodous

Anthony B Reed

Ryan D White

Victor J Cee

Richard Thomas Lewis

Shimin Xu

Aaron C Siegmund

John Gordon Allen

Xianghong Wang

Matthew Paul Bourbeau

Steven F Bellon

Randall W Hungate

Alan C Cheng

Daniel B Horne

Russell Graceffa

Jing M Xu

Qingping Zeng

Stuart C Chaffee

Adrian Leonard Smith

Paul A Tempest

Michele Potashman

Philip R Olivieri

Murielle M Veniant-Ellison

Gregory J Habgood

Nick A Paras

Vijay Keshav Gore

Holly L Deak

Guo-Qiang Cao

Marian C Bryan

Stephanie J Mercede

Chenera Balan

Ingrid M Fellows

Frenel Fils DeMorin

George Erich Wohlhieter

James Thomas Rider

Douglas A Whittington

William H Buckner

Dante Romanini

Oliver Thiel

Jing Xu

Partha Chakrabarti

Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)

Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Na1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Na1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

Potent and selective inhibitors of Nav1.7

[object Object]

Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors

The present invention describes pyrimidine compounds of Formula I that are useful as anaplastic lymphoma kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.

Pyrimidine compounds that inhibit anaplastic lymphoma kinase

Pyridine and pyrimidine compounds: or a pharmaceutically acceptable salt thereof, wherein m, n, R, R, R, R, R, R, R, X, X, X, X, X, X, X, X, and Y are as defined in the specification; or a pharmaceutically acceptable salt thereof, wherein ring A, m, n, y, R, R, R, R, R, R, R, R, X, X, and ring A are as defined in the specification; and or a pharmaceutically acceptable salt thereof, wherein m, n, y, R, R, R, R, R, R, R, X, X, and ring A are as defined in the specification; compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A, L, R, R, R, Rand m are as defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, ankylosing spondylitis, pain and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

Phthalazine compounds as p38 map kinase modulators and methods of use thereof

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A, A, B, Rand Rare defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use

The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein.  The invention also relates to the therapeutic use of such compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

Heterocyclic modulators of PKB

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein B, R, R, R, Rand Rare d.efined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

Phthalazine compounds and methods of use

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A, B, R, R, Rand Rare defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of P38 map kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

Imidazo- and triazolo-pyridine compounds and methods of use thereof

Pyrimidine ethers and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

Vanilloid receptor ligands and their use in treatments

Growing community of inventors

Moorpark, CA, United States of America

James Richard Falsey